Topic
melanoma
Moderna skin cancer vaccine trial shows promise in preventing recurrence
A phase 3 clinical trial evaluating Moderna and Merck's personalized mRNA skin cancer vaccine has met its primary goals in delaying recurrence.
Moderna's melanoma vaccine meets primary goal, sparks growth hopes
Moderna's personalized mRNA cancer vaccine Intismeran met its primary endpoint in a late-stage trial combined with Merck's Keytruda, sparking a major market rally.